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Allogeneic HCT survivors with cGvHD were signiﬁcantly
more likely to report frailty than autologous HCT survivors
(29% vs. 10%, p¼0.004), but the prevalence rate for frailty
among allogeneic HCT survivors without cGvHD was
comparable to autologous HCT survivors (14% vs. 10%, p¼0.4).
Multivariable logistic regression revealed that allogeneic
HCT survivors with cGvHDwere 4.6 foldmore likely to report
frailty than autologous HCT survivors (OR¼4.6, 1.6-13.2,
p¼0.004). Of note, age at HCT, age at study participation,
race/ethnicity, year of HCT, and diagnosis were not associated
with frailty.
Conclusions: Our study demonstrates that the prevalence of
frailty among older survivors of allogeneic HCTwith a history
of cGvHD is about three times that seen among older
individuals in the general population, as well as that seen
among autologous HCT recipients. On the other hand, the
prevalence of frailty among older survivors of autologous
HCT as well as allogeneic HCT recipients without cGvHD is
comparable to that in the general population. Lower income,
possibly reﬂecting compromise in nutrition, or access to
medical care, is associated with increased prefrailty and
frailty. The study identiﬁes vulnerable populations among
older HCT survivors needing close monitoring to prevent and
manage morbidity.60
Cardiac CT Imaging Is a Feasible Screening Strategy for
Coronary Artery Disease (CAD) in Long Term Allogeneic
Stem Cell Transplant (Allo-SCT) Survivors
Natasha A. Jain 1, Marcus Y. Chen 2, Sujata Shanbhag 2,
Prathima Anandi 1, Kit Lu 1, Priyanka A. Pophali 1, Neil Dunavin 1
, Sawa Ito 1, Eleftheria Koklanaris 1, Christopher S. Hourigan 1,
A. John Barrett 1, Minoo Battiwalla 1. 1 Hematology Branch,
National Heart, Lung, and Blood Institute, NIH, Bethesda, MD;
2 Cardiology Branch, National Heart, Lung, and Blood Institute,
NIH, Bethesda, MD
Introduction: Signiﬁcant increases in CAD risk and
cardiovascular events have been described in long-term
allo-SCT survivors compared to age and gender-matched
population controls. Since pharmacologic interventions,
such as statins, positively inﬂuence the evolution of CAD and
subsequent cardiovascular events, an effective screening
strategy is essential. Screening for CAD has hitherto relied
upon clinical assessments such as the Framingham cardio-
vascular risk score but the optimum screening strategy in
this unique population is undeﬁned.
Method: We conducted a prospective non-randomized
study using cardiac CT to evaluate Agatston coronary calcium
scoring by CT with concomitant coronary CT angiography
for screening asymptomatic allo-SCT survivors. 55 subjects
(32 males; 23 females) with a median age of 41 years (range
17 - 69) at transplant and a median follow up interval of 10
years (range: 4-21) were studied. Angiography was excluded
in 5 subjects with renal dysfunction. CAD was deﬁned as
presence of lesions on CT angio and/or calcium score > 0 (for
subjects without angiography). 10-year Framingham scores
were also calculated: 3 were classiﬁed as high risk, 5 were
intermediate and 47 were low risk.
Results: CAD was detected in 24 of 55 (44%) subjects.
Characteristics of coronary plaques were: 21.5% calciﬁed, 55%
mixed calciﬁed/non-calciﬁed, and 23.5% non-calciﬁed. Cor-
onary lesions were mostly non-obstructive (86%), but
obstructive lesions were seen in 14%. Lesion distributions by
arterial territory were: left main 12.8%, left anterior
descending 30.8%, left circumﬂex 23.1% and right coronaryartery 33.3%. Additionally, 16 (67%) patients with CAD had
either aortic root or mitral valvular calciﬁcation.
Radiation exposure during the procedure was negligible,
at a median of 0.72 mSv for the coronary calcium score and
1.12 mSv for the coronary CT angiogram. There were no
adverse events.
Coronary calcium scoring had a sensitivity of 73% (95% C.I.
55% to 85%) and a speciﬁcity of 100% (95% C.I. 86% to 100%)
compared to CT angiography. In addition, calcium score was
able to detect CAD in 2 of 5 subjects who could not have
angiograms because of renal dysfunction. Current (2010
AHA/ACC) guidelines suggest a role for coronary calcium
scoring for screening asymptomatic non-transplant in-
dividuals with intermediate Framingham risk. However,
cardiac CT detected CAD in 18 of 47 (38.3%) low Framingham
risk survivors. Coronary calcium scoring alone may be
adequate for screening and avoids the use of IV contrast.
Conclusion: Accelerated CAD was detected in 44% of our
alloSCT survivors by cardiac CT screening. Coronary calcium
score with or without CT angiogram is a safe, feasible and
sensitive screening technique for CAD. It is informative even
in asymptomatic, low-risk survivors and is far more sensitive
than the Framingham risk score.61
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Allogeneic transplantation is the only curative treatment
for the hematological complications of Fanconi anemia.
Survival after transplantation has improved dramatically
over the past decade, however, only limited data are avail-
able regarding late complications after transplantation.
Therefore, we studied late complications in 157 patients who
survived for at least 2 years after their ﬁrst transplantation,
between 1988 and 2011. The median follow up of this cohort
is 9 years (range 2e25). Marrow failure was the most com-
mon indication for transplantation (80%) and most (71%)
grafts were from a related donor. Bone marrow was the
predominant graft (89%). Chimerism studies were available
for 147 of 157 (94%) patients; at last follow up, 110 of 147
(76%) patients reported donor chimerism >95%, 27 (18%),
between 90-95%, 8 (5%), <90% and the remaining 2 patients
(1%), <30%. The 2-year cumulative incidence of chronic
GVHD at 2 years was 35%. At study entry 32 of 55 patients
with chronic GVHD were receiving immunosuppressive
treatment. The probabilities of overall survival for patients
who survived at least 2 years was 95%, 90% and 79%, 5, 10 and
15 years after transplantation. Late mortality was associated
with transplant period (prior to 2003), history of chronic
GVHD and, occurrence of squamous cell carcinoma (SCC).
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without chronic GVHD was 97% and 76%, respectively
(p¼0.002). The cumulative incidence of squamous cell
carcinoma (SCC) at 10yswas 8% and at 15yswas 14%. SCC was
more common in those who reported chronic GVHD
compared to those without chronic GVHD (14% vs. 4%,
p¼0.03). Endocrine dysfunction was common with
hypogonadism in 40% of patients and hypothyroidism in 25%.
Normal pregnancies occurred in 4 females with normal
offspring. Neurological, auditory, visual, pulmonary, hepatic
and renal complications were disease-related or transplant
procedure but occurred at substantially lower frequencies.
There were 20 deaths (13%) that occurred after 2 years. SCC
was the predominant cause of death (n¼8). Other causes of
death include, chronic GVHD (n¼6), rejection (n¼2),
pulmonary complications (n¼2), urinary sepsis (n¼1) and
hepatitis C (n¼1). In summary, most long-term survivors are
disease-free and lead functional lives. However, for those
patients with late complications of transplantation or its
effects, efforts must be directed at lowering morbidity and
mortality.62
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Allogeneic hematopoietic cell transplantation (allo HCT)
survivors are at risk for long-term mortality from late
complications. Low socioeconomic status (SES) has been
shown to be associated with health care disparities including
poor access and adverse outcomes in a variety of health
conditions. Early post-transplant care is typically well
coordinated through the patients transplant center.
However, as patients transition back to their community
providers, it is possible that patients with less resources and
poor access to healthcare would be at higher risk for
complications and mortality. Hence, we hypothesized that
SES would be associated with survival and non-relapseFigure. Overall survival by SES in 1 year allogeneic HCT survivorsmortality (NRM) in long-term survivors after allo HCT. We
studied 283 consecutive allo HCT recipients transplanted
between 2003 and 2012 who had survived for at least 1 year
in remission. Median annual household income was
estimated using Census tract data and from ZIP code of
residence at the time of transplant. SES categories were
determined by recursive partitioning analysis and were
categorized into low SES (<$51,000/yr, N¼203) and high SES
($51,000/yr, N¼80). Low SES patients were more likely to
be of non-White race (10% vs. 1%), otherwise there were no
notable differences between the two cohorts, including
diagnosis, disease status, HCT-Comorbidity Index scores,
donor source, graft source and conditioning regimen
intensity. In univariate analysis, low SES patients had
signiﬁcantly worse survival (Figure) and NRM but
comparable incidence of relapse mortality. In multivariate
analyses that adjusted for patient, disease and transplant
characteristics, patients with low SES had signiﬁcantly
higher risks of all-cause mortality (HR 1.98, 95% CI 1.16-3.37,
p¼0.012) and NRM (HR 2.22, 95% CI 1.09-4.50, p¼0.028), but
similar risks of relapse mortality (HR 1.01, 95% CI 0.44-2.34,
p¼0.97) compared to high SES patients. Common causes of
death in low SES and high SES patients included disease
relapse (39% vs 47%), infections (20% vs 12%), organ toxicity
(17% vs 18%) and chronic graft-versus-host disease (11% vs
18%). In conclusion, 1 year allo HCT survivors with low SES
have inferior overall survival that is driven by higher NRM
compared to patients with high SES. More research is needed
to understand the reasons for these health care disparities
and identify interventions to mitigate them.63
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Background: Venous Thromboembolism (VTE) is a common
late effect after Hematopoietic Stem Cell Transplant with
wide variation in reported frequency of incidence (1-20% of
patients). There is lack of data with respect to risks and
outcomes of VTE, unlike sinusoidal obstruction syndromes
(SOS) for which adequate literature is available. Therefore,
optimal approach for prevention and management of VTE in
HSCT patients is unknown. We sought to conduct a
meta-analysis of VTE incidence and evaluate its risk factors in
HSCT patients.
Methods: A comprehensive search of several databases from
each database’s earliest inception to June 2, 2014 in any
language was conducted by an experienced medical
librarian. The databases included Ovid Medline In-Process &
Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE,
Ovid CCT and Scopus. To avoid publication bias, we also
searched annual meeting abstracts from ASBMT, EBMT, ASH,
SIOP, and ISTH. The electronic search generated 755 articles.
Only 34 studies met the strict selection criteria. Case reports,
review articles, meta-analysis, postmortem reports, and
solid organ transplants were excluded. Two investigators
independently analyzed the studies for ﬁnal selection. Both
autologous and allogeneic HSCTs were included for any
